GlassScriptPhysician profile
David H Kraus
NPI 1225015712
$87,089.29
in general payments reported to CMS, 2019-2025
35 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $681 · 2021: $491 · 2022: $14K · 2023: $61K · 2024: $6,375 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $19K · Food and Beverage: $5,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,590.00 |
| Travel and Lodging | $19,435.52 |
| Food and Beverage | $5,273.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $78,788.39 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Amgen INC. | $1,108.91 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $891.75 | 2019-2025 | |
| Pfizer INC. | $725.23 | 2019-2025 | |
| Abbott Laboratories | $682.10 | 2019-2025 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.39 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $476.22 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $420.22 | 2021-2025 | Amvuttra, Onpattro |
| Akcea Therapeutics, INC. | $396.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $333.89 | 2019-2025 | Wainua, Farxiga |
| Novo Nordisk INC | $317.24 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $314.14 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $263.32 | 2022-2023 | |
| Bridgebio Pharma, INC. | $227.95 | 2025 | Attruby |
| Philips North America LLC | $225.39 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $201.06 | 2019-2024 | |
| Biotronik INC. | $197.04 | 2019-2025 | Biomonitor, Pamira, Acticor 7 Vr-T Dx |
| Impulse Dynamics (USA) INC. | $183.85 | 2022-2023 | Optimizer, Optimizer |
| Regeneron Healthcare Solutions, INC. | $162.54 | 2019-2025 | Evkeeza |
| Lundbeck LLC | $114.83 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $89.31 | 2019-2022 | |
| Esperion Therapeutics, INC. | $75.14 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $67.58 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.93 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $43.17 | 2019 | |
| Portola Pharmaceuticals, LLC | $39.90 | 2019 | |
| Inspire Medical Systems, INC. | $34.45 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $27.98 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.75 | 2025 | Injectafer |
| Daxor Corporation | $22.65 | 2024 | Bva-100 |
| United Therapeutics Corporation | $20.02 | 2020 | |
| Vifor Pharma, INC. | $19.73 | 2019 | |
| Baxter Healthcare | $19.45 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $18.21 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kraus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.